Contrast-enhanced US demonstrated a sensitivity and area under the receiver operating characteristic curve noninferior to contrast-enhanced MRI in the detection of residual hepatocellular carcinoma after lenvatinib and anti–programmed cell death protein-1 antibody therapy.